Neudata Neudata - Alternative Data Intelligence
Email info@neudata.co
  • Solutions

      DATA BUYERS

      New starter

      Build your alternative data program with Neudata

      Experienced data buyer

      Increase the success of your alternative data program

      Compliance focused

      Comply with regulatory requirements while reducing risk

      Private equity & venture capital

      Intelligence through the deal lifecycle

      Professional services

      Level up your data scouting efforts for client projects

      DATA OWNERS

      List your data for free

      Get your data product found by 1,000+ qualified buyers

      Lead generation

      Fill your sales pipeline

      Consulting

      Unlock your data’s profit potential

  • Events
  • About
    • People
    • Careers
    • Press Resources
    • Contact
  • News
  • Sign in
Request a trial

Alternative Data News and Insight

  • All
  • Intelligence
  • Literature Review
  • Signal
  • Tidbits
  • Sentry
  • News
  • Sentry Report
  • Events
  • Blog
  • April Tidbits: Alternative Alternative Datasets

    In this month’s tidbits, we look back at the most popular Neudata Intelligence themes from the past year, share some new alternatives to alternative datasets, inform our quant readers of a new back testing opportunity and draw attention to more commercial and academic interest in intellectual property data.
    Tidbits 30 Apr 2019
  • Contemplating Multimodal Sentiment Analysis

    Sentiment can be found in places other than text-based language. We introduce an academic paper that correlates market sentiment with news article photos and consider whether or not multimodal sentiment analysis (derived from audio, images, video) has a future in the landscape of alternative data.
    Intelligence 18 Apr 2019
  • Alternative Data for Healthcare Investors (Part II): Predicting Clinical Trial Outcomes

    Drug development pipelines are the foundation on which pharma and biotech companies build their future success. Consequently, share price volatility is commonplace around the announcement of clinical trial results. In this report, we expand on our previous work - Using Alt Data to Evaluate Pharma Pipelines – by exploring a) the impact of clinical trial outcomes on the market value of pharma and biotech companies and b) predictive factors that could be used to estimate clinical trial outcomes.
    Intelligence 11 Apr 2019
  • 5G rollout: Identifying the winners and losers using alt data

    2019 marks the start of the next generation of communication: 5G. While the US and China rollout the technology using existing 4G networks and infrastructure, we look forward to 2025 - when 5G is expected to be operating without any reliance on its predecessor. In this Intelligence report, we use alternative data to try to answer 1) which telco operators are likely to dominate the market six years from now, and 2) how much they stand to earn with their innovations.
    Intelligence 3 Apr 2019
  • Crowdsourced employee reviews: a predictor of stock returns?

    A growing amount of literature examines the relationship between financial performance and employee sentiment, as measured by crowdsourced company ratings and reviews. In particular, recent studies assess the ability of these datasets to forecast stock returns and earnings surprises, since changes in employee satisfaction levels can signal shifts in the economic condition of the firm. In this report we 1) highlight the predictive characteristics of employee feedback data, 2) discuss the limitations of these datasets and offer possible solutions, and 3) provide a market summary of crowdsourced employee review datasets.
    Intelligence 28 Mar 2019
  • March Tidbits: To Infinity and Beyond

    Highlights of this month’s tidbits include: a shake-up in the satellite & aerial space, agricultural data trials, movements in both SDK and cell-tower location data, and yet another edition of Alt Data Around the World – this time with the exciting new addition of Latin America.
    Tidbits 26 Mar 2019
  • An Alt Data Analysis of Brexit

    The public narrative around Brexit has reached the point where it is now impossible to see the woods for the trees. In the following piece, we ask 1) What even is Brexit? 2) How can an investor better gauge their exposure to it? 3) How can we obtain higher-frequency, lower-latency macro indicators? 4) Is it possible to preempt corporate reactions?
    Intelligence 21 Mar 2019
  • Alternative Data for Healthcare Investors (Part I): A Primer on Real-World Data

    There is an ever-expanding supply of alternative data sources that can be utilised by pharma, biotech, and medtech investors. In this piece, we turn our attention away from “traditional” clinical trial data towards Real-World Data (RWD). Namely, data that is generated in real-world medical settings. In the first of a series of healthcare-focused Neudata intelligence articles, we provide a primer on the RWD landscape, including 1) an introduction to healthcare data and how RWD is defined, 2) the different types and sources of RWD, and 3) regional differences in the collection and availability of RWD.
    Intelligence 14 Mar 2019
  • Interserve’s failure: Making the case for procurement data

    In this Intelligence report, we examine how public procurement data could have flagged the construction giant, Interserve’s, demise ahead of time. We also highlight a few suitable alternative data providers for readers interested in incorporating this type of data in their analysis.
    Intelligence 6 Mar 2019
  • February Tidbits: The Opening of Chaos

    In this month’s tidbits, we journey into international waters with coverage of domestic alt data events in China and Japan, before moving onto a data provider traction round-up and a new Neudata record for historical data length.
    Tidbits 27 Feb 2019
1 … 93 94 95 96 97 98 99 100 101 … 104
Neudata Ltd © 2025. All rights reserved.
  • Terms and Conditions
  • Privacy Statement
  • Cookies